Date:8/30/2010

and such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal years 2010 and 2011, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2010 and 2011.  A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.ThermoGenesis Corp.Web site: http://www.thermogenesis.comContact: Investor Relations+1-916-858-5107, orir@thermogenesis.com
'/>"/>

SOURCE ThermoGenesis Corp. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal 2008 on September 9, 2008
2. ThermoGenesis Reports Record Quarterly Revenues of $7.2 Million; Full Year Revenues Increase 31 Percent
3. ThermoGenesis Announces Distribution Agreement for Bone Marrow Stem Cell Device
4. ThermoGenesis Corp. to Announce First Quarter Fiscal 2009 Results on November 6, 2008
5. ThermoGenesis Presentation at Rodman & Renshaw Conference
6. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2009 Results on February 4, 2009
7. ThermoGenesis Says FDA Concurs with Plan for Previously Announced AXP(TM) Bagset Recall
8. ThermoGenesis Announces Abstracts to Be Presented at Upcoming Stem Cell Therapy Conference
9. ThermoGenesis Provides Update on Fiscal 2009 Results
10. ThermoGenesis Announces Expanded Collaboration With Celling Technologies
11. ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results